Losartan Recalled Expanded: Ten Lots Recalled

Posted on 01/16/2019Back

On January 3, 2019, the FDA issued yet another recall of Losartan Potassium tablets. The first recall was issued November 9, 2018 and involved 2 lots. Now, Torrent Pharmaceuticals Limited is recalling a total of 10 lots due to the unexpected impurity N-nitrosodiethylamine (NDEA) found in the drug.

Losartan is a medication used to treat hypertension. It was recalled following the recall of similar drugs Valsartan and Irbesartan for containing NDEA and N-nitrosodimethylamine (NDMA). These substances are classified as probable human carcinogens by the Environmental Protection Agency. Exposure to NDEA can cause:

  • Liver Cancer
  • Stomach Cancer
  • Colon Cancer
  • Intestinal Cancer
  • Prostate Cancer (Must be diagnosed before age 60)
  • Lower Esophageal Cancer
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Leukemia
  • Pancreatic Cancer

The products subject to recall can be found on the FDA’s website, which lists the product description, batch/lot number, and expiration date.

If you or a loved one was diagnosed with liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma after taking Losartan, please contact us. We have over 30 years of experience handling dangerous drug cases. At GoldenbergLaw, we deliver the Gold standard advocacy you deserve.

Category Dangerous Drugs